CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Farletuzumab +1 moredrug
Likely dose
Chemo Plus Far 175 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00318370
NCT00318370Phase 2Completed
CompareCT.gov

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Morphotek·interventional·Posted Apr 26, 2006·Updated Sep 9, 2015

In Brief

A Phase 2 clinical trial evaluating Farletuzumab and Chemo Plus Far for Ovarian Cancer and 2 related conditions. Completed, enrolled 58 participants across 20 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer. MORAb-003 is a monoclonal antibody directed against an antigen on most ovarian cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
CountriesGermany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 26, 2006
Enrollment StartMay 1, 2006
Primary CompletionFeb 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.2 years ago

Interventions

Farletuzumabdrug

Weekly Farletuzumab infusions Dose dependent on dosing group

Chemo Plus Fardrug

Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.